Liver Abscess: Pyogenic and Amoebic — Comprehensive Review

PART I — PYOGENIC LIVER ABSCESS (PLA)

Epidemiology & Pathogenesis

1. Biliary (ascending cholangitis) — most common; via the bile duct
2. Portal venous pyemia — from intra-abdominal septic foci
3. Hematogenous — via hepatic artery from systemic bacteremia
4. Direct extension/trauma — penetrating injury or adjacent septic focus
5. Cryptogenic — ~40% of cases; no identifiable source; associated with Klebsiella pneumoniae and linked to underlying colorectal cancer (4× higher incidence; colonoscopy recommended)

Microbiology

• Gram-negative bacilli: E. coli, Klebsiella spp., Proteus, Pseudomonas
• Gram-positive: Streptococcus spp. (particularly S. milleri/anginosus group); US studies identify streptococci as most common
• Anaerobes: Bacteroides fragilis, Fusobacterium necrophorum, anaerobic streptococci
• Special circumstances: S. aureus (children, septicemia); Candida spp. (immunocompromised); K. pneumoniae monomicrobic (cryptogenic PLA — high virulence, metastatic spread to eye/CNS)
• Biliary origin: E. coli, Klebsiella, Enterococcus; enteric origin: anaerobes predominate

Clinical Presentation

• Leukocytosis: ~90%
• Elevated alkaline phosphatase: ~80%
• Hyperbilirubinemia: ~50%
• Transaminitis: ~50%
• Hypoalbuminemia, normochromic normocytic anemia
• Blood cultures positive in ~50% of cases

Diagnosis

• CT with IV contrast — most sensitive (~95%); shows hypoattenuated lesion with peripheral rim enhancement; identifies loculations, communicating biliary pathology, and extrahepatic disease. First-line imaging of choice.
• Ultrasound — sensitivity ~85–90%; preferred initial modality in pediatrics; guides percutaneous drainage
• Plain chest X-ray — right pleural effusion, elevated right hemidiaphragm in ~50%
• MRI — alternative; superior for cyst wall delineation; less commonly used
• Tagged WBC scan — rarely used, reserved for specific scenarios

• Blood cultures (ideally before antibiotics)
• Image-guided aspiration with Gram stain, culture & sensitivity
• Serologic and fecal testing for E. histolytica in patients with epidemiologic risk factors

Differential Diagnosis

• Amoebic liver abscess — single, right-lobe, "anchovy paste" content; travel history; serology positive
• Hepatocellular carcinoma or metastatic liver disease (cystic/necrotic)
• Simple hepatic cyst / biloma
• Echinococcal (hydatid) cyst
• Hepatitis (acute, fulminant)
• Cholangitis
• Subphrenic or subhepatic abscess
• Pancreatic or perihepatic collections

Multiple abscesses strongly suggest pyogenic etiology; a solitary right-lobe abscess with travel history favors amoebic origin. Imaging alone cannot reliably distinguish the two — serology is essential.

Treatment

1. Antibiotics

• First-line: Piperacillin/tazobactam monotherapy or ceftriaxone + metronidazole
• High-risk/biliary instrumentation/transplant: Carbapenems (for ESBL coverage)
• Duration: IV therapy for 14 days → oral completion for total 4–6 weeks, guided by clinical response and imaging resolution

2. Percutaneous Drainage (standard of care)

• Catheter placement recommended for abscesses >5 cm — superior outcomes vs. needle aspiration alone
• Safe for very large (>10 cm) abscesses (may require multiple catheters)
• Abscesses <3 cm: aspiration alone if technically feasible (guides antibiotic choice)
• Catheters remain until output is low and clear (usually ~7 days)
• Bile in drain output → suspect biliary communication → investigate with HIDA/MRCP/ERCP → may require sphincterotomy or percutaneous biliary drain

3. Surgical Drainage or Resection

• Percutaneous drainage fails or is incomplete
• Multiloculated abscess not amenable to catheter drainage
• Ruptured abscess with peritonitis
• Concurrent intra-abdominal pathology requiring surgery (e.g., simultaneous diverticulitis)
• Unresolved jaundice or renal impairment preventing recovery
• Biliary reconstruction needed

Efficacy: antibiotics + percutaneous drainage effective in 80–90% of patients.

Outcomes & Complications

• Delayed diagnosis
• Multiple abscesses / multiple organisms in blood cultures
• Fungal etiology
• Shock, jaundice, hypoalbuminemia
• Pleural effusion, underlying biliary malignancy
• Diabetes, cirrhosis, multiorgan dysfunction

• Rupture with purulent peritonitis (abscesses >10 cm carry increased risk)
• Empyema (direct pleural extension)
• Pleural effusion (reactive or infectious)
• Pericardial effusion / rupture into pericardium (rare but life-threatening)
• Portal or splenic vein thrombosis
• Thoracoabdominal fistula
• Septic metastatic endophthalmitis — in up to 10% of diabetic patients with K. pneumoniae PLA
• Sepsis / multiorgan failure

PART II — AMOEBIC LIVER ABSCESS (ALA)

Epidemiology & Pathogenesis

• Males affected 8–10× more than females (striking predominance)
• Peak incidence: third to fifth decade of life
• In the USA: predominantly young, often Hispanic, adult males with travel history

1. Ingestion of mature E. histolytica cysts or trophozoites via fecally contaminated food/water
2. Cyst wall degraded in intestine → trophozoites released → multiply in colonic lumen
3. Trophozoites invade intestinal mucosa → enter mesenteric veins → portal circulation → liver (typically 2–4 months after colitis)
4. In the liver: trophozoites obstruct venules → thrombosis and infarction of hepatic parenchyma → liquefactive necrosis ("anchovy paste" content — thick, brown, proteinaceous fluid with necrotic hepatocytes and trophozoites)

Clinical Presentation

• Onset: typically 8–20 weeks after return from endemic area
• Fever: ~80% (may be less dramatic than PLA)
• Right upper quadrant pain (often dull, constant): ~60%
• Cough, night sweats, malaise, weight loss, hiccough — common
• Diarrhea: only ~30% (concurrent active intestinal amebiasis is uncommon)
• Jaundice: ~10% (less common than PLA)
• Marked hepatomegaly — especially in travelers vs. endemic residents

• Leukocytosis (eosinophilia is NOT typically seen — E. histolytica is a protozoan, not a tissue-invasive helminth)
• Elevated ALP (~80%)
• Elevated transaminases
• No eosinophilia (distinguishes from parasitic worm infections)

Diagnosis

• Ultrasound: round, well-defined, hypoechoic (sometimes anechoic) mass; predominantly in right lobe; tends to be solitary (vs. multiple in PLA)
• CT: low-density mass with peripheral enhancing rim; cannot reliably distinguish from PLA
• MRI: low signal on T1, high signal on T2; superior capsule delineation
• CXR: elevation of right hemidiaphragm in ~50%; right pleural effusion

• Amebic serology (antibody): sensitive, but 1/3 of patients with prior E. histolytica infection have persistent antibodies without active disease
• Antigen testing (stool or serum): more specific for active infection
• Antibodies detectable in serum 7–10 days after symptom onset in >90% of patients
• Stool examination for trophozoites/cysts: unreliable (intermittent shedding; simultaneous intestinal disease uncommon in those with ALA)

• Content: "anchovy paste" — dark brown, thick, acellular, proteinaceous fluid; trophozoites found at abscess wall, not in the central pus
• Aspirate antigen or PCR testing: most sensitive method; sensitivity 75–100%, specificity >90%
• PCR is 100% sensitive before treatment (vs. ~70% after treatment begins)

Differential Diagnosis (ALA vs. PLA — Key Distinctions)

Treatment

1. Medical Treatment (mainstay — >90% respond without drainage)

• Metronidazole 500–750 mg orally/IV 3× daily × 7–10 days — first-line; clinical improvement in >90%
• Tinidazole 2 g orally once daily × 5 days — alternative; better tolerated

• Paromomycin 25–30 mg/kg/day orally in 3 divided doses × 7 days
• Diiodohydroxyquin (iodoquinol) 650 mg orally 3× daily × 20 days
• Diloxanide furoate 500 mg orally 3× daily × 10 days

2. Percutaneous Aspiration / Drainage (selective)

• Large abscess (especially >10 cm) — risk of spontaneous rupture
• Failure to respond to metronidazole within 72–96 hours
• Left lobe abscess (high risk of rupture into pericardium)
• Diagnostic uncertainty (cannot exclude PLA)
• Imminent rupture

3. Surgical Treatment

• Rupture into peritoneal cavity — peritonitis (emergency laparotomy, peritoneal lavage, drainage)
• Rupture into pericardium (rare, life-threatening emergency)
• Thoracoabdominal fistula not amenable to percutaneous management
• Secondary bacterial superinfection not responding to antibiotics + aspiration

Complications of ALA (Parasitic Liver Disease)

• Rupture into peritoneal cavity (most common complication, ~7% of cases): severe peritonitis, septic shock
• Pleuropulmonary extension (most common route after peritoneal): right pleural effusion, empyema, hepatobronchial fistula, lung abscess — the lung is the second most common extraintestinal site after the liver
• Rupture into pericardium (left lobe abscesses): pericardial tamponade, constrictive pericarditis — high mortality
• Secondary bacterial superinfection — converts to mixed pyogenic-amoebic abscess
• Cerebral amebiasis (hematogenous spread — rare but nearly uniformly fatal)
• Cutaneous amebiasis (perianal extension)

PART III — PARASITIC DISEASES OF THE LIVER: COMPLICATIONS OVERVIEW

Echinococcosis (Hydatid Disease)

• Rupture into peritoneal cavity → anaphylaxis, secondary seeding (catastrophic)
• Biliary communication → cholangitis, obstructive jaundice
• Secondary infection → pyogenic superinfection
• Venous obstruction → portal hypertension
• Sepsis

• Goal: remove cyst intact without spillage of scoleces
• Pre-operative aspiration of cyst contents + injection of scolicidal agent (ethyl alcohol or 20% sterile saline) before resection
• If aspirate is bilious (biliary communication suspected): resect without alcohol injection (risk of sclerosing cholangitis)
• Approach: open or laparoscopic depending on cyst features/location
• Albendazole started 4 days before surgery, continued ≥4 weeks postoperatively (mebendazole as alternative, less well-absorbed, ≥3 months)
• PAIR (Puncture-Aspiration-Injection-Reaspiration): minimally invasive option for select cases

Summary Table: Key Comparative Features

• Current Surgical Therapy, 14th edition (Mulholland/Cameron)
• Mulholland and Greenfield's Surgery: Scientific Principles and Practice, 7th edition
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease